Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia

References

• Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015 Apr;29(4):282–294.
   PubMed Web of Science ®Google Scholar
• Mantha S, Miao Y, Wills J, et al. Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis. 2017 May;43(4):514–518.
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Martin CG, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001 Feb 15;19(4):1137–1146.
   PubMed Web of Science ®Google Scholar
• Denduluri N, Patt DA, Wang Y, et al. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr Canc Netw. 2015 Nov;13(11):1383–1393.
   PubMed Web of Science ®Google Scholar
• Goodnough LT, DiPersio JF. Issues in the management of cancer-related thrombocytopenia. Oncology (Williston Park). 2002 Nov;16(11):1558–1567; discussion 1570, 1572-4
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000 Mar 7;132(5):364–368.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Hamlin PA, Gabrilove J, et al. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol. 2007 Nov;18(11):1842–1850.
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001 Dec 1;98(12):3241–3248.
   PubMed Web of Science ®Google Scholar
• Basser RL, O’Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. 2002 Apr 1;99(7):2599–2602.
   PubMed Web of Science ®Google Scholar
• Tang B, Huang L, Liu H, et al. Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation. Blood Adv. 2020 Aug 25;4(16):3829–3839.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735.
   Web of Science ®Google Scholar
• Kilpatrick K, Shaw JL, Jaramillo R, et al. Occurrence and management of thrombocytopenia in metastatic colorectal cancer patients receiving chemotherapy: secondary analysis of data from prospective clinical trials. Clin Colorectal Cancer. 2020 Nov 1. DOI:10.1016/j.clcc.2020.10.004.
   PubMed Web of Science ®Google Scholar
• Soff GA, Miao Y, Bendheim G, et al. Romiplostim treatment of chemotherapy-induced thrombocytopenia. J Clin Oncol. 2019 Nov 1;37(31):2892–2898.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Parnes AD, Goodarzi K, et al. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica. 2021 Apr 1;106(4):1148–1157.
   PubMed Web of Science ®Google Scholar
• Hoilund-Carlsen PF, Hess S, Werner TJ, et al. Cancer metastasizes to the bone marrow and not to the bone: time for a paradigm shift! Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):893–897.
   PubMed Web of Science ®Google Scholar
• Franchini M, Veneri D, Lippi G. Thrombocytopenia and infections. Expert Rev Hematol. 2017 Jan;10(1):99–106.
   PubMed Web of Science ®Google Scholar
• Stasi R. How to approach thrombocytopenia. Hematology. 2012;2012(1):191–197.
   PubMedGoogle Scholar
• Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer. 1997 Sep 15;80(6):1134–1140.
   PubMed Web of Science ®Google Scholar
• Gross-Goupil M, Fourcade A, Blot E, et al. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012 Mar;48(5):721–727.
   PubMed Web of Science ®Google Scholar
• Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern cooperative oncology group. J Clin Oncol. 2009 Aug 10;27(23):3778–3785.
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Harbeck N, Groll De Rivera I, et al. Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer. Oncology. 2010;79(3–4):197–203.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2009 Jul 1;27(19):3217–3224.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20;26(21):3543–3551.
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009 Jul 10;27(20):3385–3390.
   PubMed Web of Science ®Google Scholar
• Aspinall SL, Good CB, Zhao X, et al. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer. 2015 Feb 18;15(1):62.
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Reiner M, Morrow PK, et al. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol. 2015 Mar;93(3):203–210.
   PubMed Web of Science ®Google Scholar
• Hanna RK, Poniewierski MS, Laskey RA, et al. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2013 Apr;129(1):74–80.
   PubMed Web of Science ®Google Scholar
• Wilde MI, Faulds D. Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159–171.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol. 2000 Apr;37(2 Suppl 4):28–34.
   PubMed Web of Science ®Google Scholar
• Kuter DJ. New thrombopoietic growth factors. Blood. 2007 Jun 1;109(11):4607–4616.
   PubMed Web of Science ®Google Scholar
• Tepler I, Elias L, Smith JW 2nd, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996 May 1;87(9):3607–3614.
   PubMed Web of Science ®Google Scholar
• Cantor SB, Elting LS, Hudson DV Jr., et al. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer. 2003 Jun 15;97(12):3099–3106.
   PubMed Web of Science ®Google Scholar
• Consensus Committee of Chemotherapy Induced Thrombocytopenia CSoCO. [Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)]. Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]. 2018 Sep 23;40(9):714–720.
   PubMedGoogle Scholar
• Al-Samkari H, Grace RF, Kuter DJ. The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020;11:2040620720912992.
   Web of Science ®Google Scholar
• Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017 Apr 20;376(16):1540–1550.
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Dusheiko GM, Giannini EG, et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014 Feb;146(2):442–52 e1.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Marshall AL, Goodarzi K, et al. Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol. 2018 Jul;182(1):106–113.
   PubMed Web of Science ®Google Scholar
• Nagrebetsky A, Al-Samkari H, Davis NM, et al. Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies. Br J Anaesth. 2019 Jan;122(1):19–31.
   PubMed Web of Science ®Google Scholar
• Barger TE, Boshier A, Jawa V, et al. Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global registry. Blood. 2018;132(Suppl 1):2427.
   PubMedGoogle Scholar
• McElroy PL, Wei P, Buck K, et al. Romiplostim promotes platelet recovery in a mouse model of multicycle chemotherapy-induced thrombocytopenia. Exp Hematol. 2015;43(6):479–487.
   PubMed Web of Science ®Google Scholar
• Demeter J, Istenes I, Fodor A, et al. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma [Case Reports]. Pathol Oncol Res. 2011 Mar;17(1):141–143.
   PubMed Web of Science ®Google Scholar
• Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017;64(8):e26473.
   Web of Science ®Google Scholar
• Al-Samkari H, Marshall AL, Goodarzi K, et al. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica. 2018;103(4):e169–e172.
   PubMed Web of Science ®Google Scholar
• Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2014 May;22(5):1217–1222.
   PubMed Web of Science ®Google Scholar
• Dardis C, Milton K, Patel N. Thrombopoietin receptor agonists are effective in treating chemotherapy-induced thrombocytopenia in patients with gliomas undergoing myelotoxic treatment. Oncomedicine. 2017;2:37–41.
   Google Scholar
• Kellum A, Jagiello-Gruszfeld A, Bondarenko IN, et al. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Curr Med Res Opin. 2010 Oct;26(10):2339–2346.
   PubMed Web of Science ®Google Scholar
• Winer ES, Safran H, Karaszewska B, et al. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study. Cancer Med. 2015 Jan;4(1):16–26.
   PubMed Web of Science ®Google Scholar
• Winer ES, Safran H, Karaszewska B, et al. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study. Int J Hematol. 2017 Dec;106(6):765–776.
   PubMed Web of Science ®Google Scholar
• Sobi announces topline phase 3 data of avatrombopag for the treatment of chemotherapy-induced thrombocytopenia 2020. [cited 2020 Dec 30]. Available from: https://www.sobi.com/en/press-releases/sobi-announces-topline-phase-3-data-avatrombopag-treatment-chemotherapy-induced
   Google Scholar
• Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med. 2019;10:313–321.
   PubMed Web of Science ®Google Scholar
• Harker LA, Hunt P, Marzec UM, et al. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood. 1996 Mar 1;87(5):1833–1844.
   PubMed Web of Science ®Google Scholar
• Harker LA, Marzec UM, Hunt P, et al. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood. 1996 Jul 15;88(2):511–521.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Van Cott EM, Kuter DJ. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. Ann Hematol. 2019 Mar;98(3):581–588.
   PubMed Web of Science ®Google Scholar
• Psaila B, Bussel JB, Linden MD, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012 Apr 26;119(17):4066–4072.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Smolensky Koganov E, Forde EE, et al. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018 Sep 28;16(12):2515–2519.
   Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment. Semin Thromb Hemost. 2020 Apr;46(3):275–288.
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Giannini EG, Tayyab G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012 Aug 23;367(8):716–724.
   PubMed Web of Science ®Google Scholar
• Virk ZM, Kuter DJ, Al-Samkari H. An evaluation of avatrombopag for the treatment of thrombocytopenia. Expert Opin Pharmacother. 2021;22(3):273-280.
   PubMedGoogle Scholar
• Kim ES. Lusutrombopag: first global approval. Drugs. 2016 Jan;76(1):155–158.
   PubMed Web of Science ®Google Scholar
• Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997 May 1;89(9):3118–3128.
   PubMed Web of Science ®Google Scholar
• Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997 Feb 6;336(6):404–409.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Patel S, Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol. 2003 Aug 15;21(16):3158–3167.
   PubMed Web of Science ®Google Scholar
• Fandrey J, Dicato M. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. Oncologist. 2009;14(Suppl 1):34–42.
   PubMedGoogle Scholar
• Erickson-Miller CL, Chadderton A, Gibbard A, et al. Thrombopoietin receptor levels in tumor cell lines and primary tumors. J Oncol. 2010;2010:135354.
   PubMedGoogle Scholar
• Columbyova L, Loda M, Scadden DT. Thrombopoietin receptor expression in human cancer cell lines and primary tissues. Cancer Res. 1995 Aug 15;55(16):3509–3512.
   PubMed Web of Science ®Google Scholar
• Erickson-Miller CL, Pillarisetti K, Kirchner J, et al. Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors. BMC Cancer. 2012 Sep 11;12(1):405.
   PubMedGoogle Scholar
• Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018 Oct 11;11(1):125.
   PubMed Web of Science ®Google Scholar
• NCCN hematopoietic growth factors: short-term recommendations specific to issues with COVID-19 (SARS-CoV-2) 2020. [cited 2020 Dec 30]. Available from: https://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf
   Google Scholar
• Al-Samkari H, Kuter DJ. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. Br J Haematol. 2018 Oct;183(2):168.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol. 2018 Dec;93(12):1501–1508.
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019 Feb 21;380(8):711–719.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019 Feb 21;380(8):720–728.
   PubMed Web of Science ®Google Scholar
• Ogura K, Goto T, Imanishi J, et al. Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas. Int J Clin Oncol. 2013 Feb;18(1):170–176.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013 May 25;381(9880):1817–1826.
   PubMed Web of Science ®Google Scholar
• Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J clin oncol: official journal of the American Society of Clinical Oncology. 2000 Aug;18(15):2852–2861.
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood. 1999 Dec 1;94(11):3694–3701.
   PubMed Web of Science ®Google Scholar
• Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood. 2000 Apr 15;95(8):2530–2535.
   PubMed Web of Science ®Google Scholar
• Geissler K, Yin JA, Ganser A, et al. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia–a randomized, placebo-controlled, double-blind safety and efficacy study. Ann Hematol. 2003 Nov;82(11):677–683.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Kuter DJ. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol. 2018 Nov;84(11):2673–2677.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H. Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease. Drugs Today. 2018 Nov;54(11):647–655.
   PubMed Web of Science ®Google Scholar